

Hold EUR 1.37 (EUR 1.60) Price EUR 1.70 Downside -19.4 %	Value Indicators: EUR DCF: 1.37	Warburg ESG Risk Score: 3.0 ESG Score (MSCI based): 3.0 Balance Sheet Score: 5.0 Market Liquidity Score: 1.0	Description: Development and distribution of diagnostic products
	Market Snapshot: EUR m Market cap: 20.1 No. of shares (m): 11.8 EV: 17.3 Freefloat MC: 20.1 Ø Trad. Vol. (30d): 30.38 th	Shareholders: Freefloat 100.0 % Deutsche Balaton AG 24.7 % Markus Pfitzke 13.5 % Altium Growth Fund 5.2 % Bridger Healthcare Ltd. 4.8 %	Key Figures (WRe): 2021e Beta: 2.1 Price / Book: 7.9 x Equity Ratio: 41 %

Plan to issue mandatory convertible bond to finance Epi proColon Next-Gen


Epigenomics announced on Friday, June 11, after market closure, its intention to issue a subordinated mandatory convertible of up to EUR 18.15m to finance costs of operations and especially the completion of the development of an improved blood-based colorectal cancer screening test "Epi proColon Next-Gen" for which a clinical study must be carried out in the USA to obtain FDA-approval. Epi proColon Next-Gen should overcome the problems in regard to sensitivity and specificity to achieve reimbursement by CMS.

Details of the mandatory convertible: The subordinated convertible bond will be convertible into up to 15,000,000 new no-par value registered shares with a share of EUR 15m in the share capital of the company. The bond will consist of up to 181,500 notes with a nominal value of EUR 100.00 each. The notes will be non-interest-bearing and have a term until 2027. In addition to the conversion rights, it will also include a conversion obligation for all outstanding notes not converted at maturity. Subject to any anti-dilution adjustments, the conversion price per share is EUR 1.21. Each note with a nominal value of EUR 100 will be convertible into 82 no-par value registered shares.

Further procedure, backing of main shareholder Deutsche Balaton: Epigenomics will shortly mandate an investment bank for the process. Then, the convertible bond will be offered for subscription by means of a rights offering initially to existing shareholders of Epigenomics, which will also be given the option of oversubscription. In view of this, a timetable for the publication of the rights offering and the start of the subscription period are not yet available. Noteworthy is that Epigenomics has entered a back-stop agreement with its main shareholder Deutsche Balaton under which the latter has agreed to acquire all notes of up to EUR 18.15m by exercising its subscription rights and by the acquisition of notes not subscribed via subscription rights and by the way of oversubscription. The obligation is subject to certain conditions.

Negative CMS reimbursement decision required action: On January 19th 2021 the US Centers for Medicare and Medicaid Services (CMS) issued a negative reimbursement decision regarding Epigenomics' blood-based colon-cancer test Epi proColon. CMS issued a catalogue of certain evidence required to cover a test for colorectal cancer screening. The main hurdle is that a blood-based test should have sensitivity greater than, or equal to, 74% and specificity greater than, or equal to, 90% based on the studies included in the FDA labelling. The current FDA-approved blood-based test Epi proColon falls short on both (sensitivity: ~68%, specificity: ~80%). Furthermore, the decision ignored the outcome of peer-reviewed microsimulation models, which were in favour of Epi proColon.

Hold rating reiterated, PT lowered to EUR 1.37: The successful development of Epi proColon Next-Gen is our base scenario. Currently, operations are financed until mid-2022. The annual cash consumption is seen at between EUR 7m and EUR 9m. Additionally, we assume approx. USD 18m or, at current rates, EUR 15m over a two-year timeframe as a necessary investment in R&D. If approved, we would expect the new modified test to come to market in 2024. There is still an unmet medical need for colon cancer tests that are easy to process. In view of this and based on our assumptions, Epigenomics' Next-Gen test should be able to gain market share of up to ~3% by 2030/31. Up to now we have figured in the financing of the required clinical study by a loan, which would now be substituted by the proceeds of the convertible bond. The negative impact of the dilution resulting from the planned issuance of the mandatory convertible on our DCF-derived PT will be approx. 14%. Accordingly, we lower our PT from EUR 1.60 to EUR 1.37. Hold rating reiterated.




Rel. Performance vs PrimeAll:	
1 month:	30.6 %
6 months:	-63.7 %
Year to date:	-61.8 %
Trailing 12 months:	-110.0 %

Company events:	
16.06.21	AGM
11.08.21	Q2
10.11.21	Q3


FY End: 31.12. in EUR m	CAGR (20-23e)	2017	2018	2019	2020	2021e	2022e	2023e
Sales	5.8 %	1.9	1.5	1.1	0.8	0.6	0.8	1.0
Change Sales yoy		-55.6 %	-17.8 %	-26.6 %	-25.2 %	-27.2 %	30.0 %	25.0 %
Gross profit margin		86.8 %	71.3 %	76.1 %	82.8 %	81.7 %	81.7 %	85.1 %
EBITDA		-9.9	-12.6	-13.3	-11.1	-8.0	-16.4	-16.8
Margin		-533.6 %	-821.1 %	-1184.3 %	-1317.3 %	-1306.8 %	-2060.2 %	-1687.6 %
EBIT		-10.3	-12.9	-13.8	-11.6	-8.6	-17.0	-17.4
Margin		-552.0 %	-841.2 %	-1228.5 %	-1380.9 %	-1402.2 %	-2133.6 %	-1746.3 %
Net income		-10.2	-12.7	-13.2	-11.7	-8.7	-17.1	-17.5
EPS		-0.44	-0.47	-0.35	-2.02	-0.86	-1.44	-1.48
EPS adj.		-0.42	-0.49	-0.35	-1.74	-0.86	-1.44	-1.48
DPS		0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		-0.44	-0.36	-0.37	-1.66	-0.84	-1.39	-1.43
FCF / Market cap		-1.2 %	-1.7 %	-2.8 %	-14.6 %	-41.9 %	-82.0 %	-84.0 %
EV / Sales		460.5 x	368.0 x	419.4 x	73.3 x	28.2 x	42.4 x	50.8 x
EV / EBITDA		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E adj.		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield		-1.1 %	-2.1 %	-3.5 %	-18.0 %	-46.4 %	-48.6 %	-33.2 %
Net Debt		-7.2	-17.1	-11.0	-3.9	-2.8	13.7	30.5
ROCE (NOPAT)		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Guidance:	Revenues of EUR 0.4-1.0m, adjusted EBITDA of between EUR -7.0m to -9.0m							

Sales development in EUR m




Source: Warburg Research

Tests sold by regions 2023e; in %



Source: Warburg Research

EBIT development in EUR m



Source: Warburg Research


Company Background

- Epigenomics was founded in Berlin in 1998.
- Epigenomics is the innovator of the Septin9 test for the detection of different cancer types.
- The company received FDA-approval for its Septin9 colorectal cancer (CRC) test Epi proColon in April 2016.
- The patent-protected test kit is distributed directly by Epigenomics in Europe and Germany and by partners in North America.

Competitive Quality


- Epi proColon is a convenient and innovative blood test for the early detection of cancer.
- Epigenomics has an early-mover advantage with its blood-based cancer test, which should help raise awareness of Epi proColon and secure high market share once it is included in the national reimbursement list in the US.
- The tests currently available are less convenient (stool-test) and more time-consuming (colonoscopy) than blood tests. Surveys show a high acceptance rate for tests that are easy to perform, like Epi proColon.

EBT development in EUR m




Source: Warburg Research

Sales by regions 2023e; in %



Source: Warburg Research

Net income development in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value
	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	
Sales	0.6	0.8	1.0	4.5	10.5	18.1	30.7	45.9	61.0	71.1	81.1	91.8	102.1	3.0 %
Sales change	-27.2 %	30.0 %	25.0 %	353.8 %	132.5 %	72.2 %	69.7 %	49.2 %	33.0 %	16.5 %	14.2 %	13.2 %	11.2 %	
EBIT	-8.6	-17.0	-17.4	-7.5	-0.4	2.1	5.8	9.7	13.6	15.8	17.7	19.1	20.2	
EBIT-margin	-1402.2 %	-2133.6 %	-1746.3 %	-165.8 %	-3.7 %	11.5 %	18.7 %	21.1 %	22.3 %	22.2 %	21.8 %	20.8 %	19.8 %	
Tax rate (EBT)	0.0 %	0.0 %	0.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
NOPAT	-8.6	-17.0	-17.4	-5.6	-0.3	1.6	4.3	7.3	10.2	11.8	13.2	14.3	15.1	
Depreciation	0.6	0.6	0.6	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1.0	
in % of Sales	95.4 %	73.4 %	58.7 %	2.0 %	1.8 %	1.6 %	1.3 %	1.1 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	
Changes in provisions	0.0	0.0	0.0	-0.5	0.1	0.2	0.3	0.3	0.3	0.2	0.2	0.2	0.2	
Change in Liquidity from														
- Working Capital	0.4	0.0	0.0	0.8	1.7	1.9	3.2	3.8	3.8	2.5	2.5	2.7	2.6	
- Capex	0.0	0.0	0.0	1.1	1.2	1.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	
Capex in % of Sales	0.0 %	0.0 %	0.0 %	24.0 %	11.0 %	6.0 %	3.3 %	2.2 %	1.7 %	1.4 %	1.2 %	1.1 %	1.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-8.4	-16.4	-16.8	-7.9	-2.9	-1.0	0.8	3.3	6.3	9.2	10.7	11.8	12.8	
PV of FCF	-7.9	-13.9	-12.8	-5.4	-1.7	-0.5	0.4	1.4	2.5	3.2	3.4	3.3	3.2	32
share of PVs	-468.71 %			131.55 %										437.16 %

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	15.00 %	Financial Strength	3.00
Cost of debt (after tax)	4.5 %	Liquidity (share)	1.40
Market return	7.00 %	Cyclicality	1.00
Risk free rate	1.50 %	Transparency	2.00
		Others	3.00
WACC	11.67 %	Beta	2.08

Valuation (m)

Present values 2033e	-25		
Terminal Value	32		
Financial liabilities	0		
Pension liabilities	1		
Hybrid capital	0		
Minority interest	0		
Market val. of investments	0		
Liquidity	30	No. of shares (m)	26.8
Equity Value	37	Value per share (EUR)	1.37

Sensitivity Value per Share (EUR)

Beta	WACC	Terminal Growth							Delta EBIT-margin						
		2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	3.50 %	3.75 %	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
2.29	12.7 %	1.04	1.06	1.08	1.11	1.13	1.16	1.19	0.93	0.99	1.05	1.11	1.16	1.22	1.28
2.19	12.2 %	1.15	1.17	1.20	1.23	1.26	1.29	1.33	1.04	1.10	1.17	1.23	1.29	1.36	1.42
2.13	11.9 %	1.21	1.24	1.27	1.30	1.33	1.37	1.40	1.10	1.17	1.23	1.30	1.36	1.43	1.49
2.08	11.7 %	1.28	1.31	1.34	1.37	1.41	1.45	1.49	1.17	1.24	1.30	1.37	1.44	1.51	1.58
2.03	11.4 %	1.35	1.38	1.41	1.45	1.49	1.53	1.57	1.24	1.31	1.38	1.45	1.52	1.59	1.66
1.97	11.2 %	1.42	1.46	1.49	1.53	1.58	1.62	1.67	1.31	1.39	1.46	1.53	1.61	1.68	1.76
1.87	10.7 %	1.59	1.63	1.68	1.72	1.77	1.83	1.89	1.48	1.56	1.64	1.72	1.81	1.89	1.97

- Sales level in 2030/2031 reflects market share of approx.3% of unscreened CRC population
- Sales growth assumption of 3% from 2034 onwards reflects potential entry of new techniques or competitors
- EBIT margin of 15% in terminal year in line with margin level of established healthcare product companies
- Margin expectation also based on assumption of higher need for marketing effort and spending

Valuation	2017	2018	2019	2020	2021e	2022e	2023e
Price / Book	81.8 x	31.2 x	50.1 x	17.0 x	7.9 x	n.a.	n.a.
Book value per share ex intangibles	0.43	0.67	0.21	0.63	0.22	-1.21	-2.66
EV / Sales	460.5 x	368.0 x	419.4 x	73.3 x	28.2 x	42.4 x	50.8 x
EV / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / FCF	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	-1.1 %	-2.1 %	-3.5 %	-18.0 %	-46.4 %	-48.6 %	-33.2 %

*Adjustments made for: EBITDA before share-based payment expenses

Consolidated profit and loss

In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Sales	1.9	1.5	1.1	0.8	0.6	0.8	1.0
Change Sales yoy	-55.6 %	-17.8 %	-26.6 %	-25.2 %	-27.2 %	30.0 %	25.0 %
COGS	0.2	0.4	0.3	0.1	0.1	0.1	0.1
Gross profit	1.6	1.1	0.9	0.7	0.5	0.7	0.8
<i>Gross margin</i>	<i>86.8 %</i>	<i>71.3 %</i>	<i>76.1 %</i>	<i>82.8 %</i>	<i>81.7 %</i>	<i>81.7 %</i>	<i>85.1 %</i>
Research and development	4.3	6.4	7.6	3.7	3.2	10.7	10.7
Sales and marketing	8.0	8.7	9.3	7.3	3.2	3.5	3.8
Administration expenses	0.0	0.0	0.0	0.0	3.2	3.5	3.8
Other operating expenses	0.6	0.3	0.9	2.9	0.0	0.0	0.0
Other operating income	1.1	1.4	3.1	1.5	0.5	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-9.9	-12.6	-13.3	-11.1	-8.0	-16.4	-16.8
<i>Margin</i>	<i>-533.6 %</i>	<i>-821.1 %</i>	<i>-1184.3 %</i>	<i>-1317.3 %</i>	<i>-1306.8 %</i>	<i>-2060.2 %</i>	<i>-1687.6 %</i>
Depreciation of fixed assets	0.2	0.1	0.3	0.3	0.4	0.4	0.4
EBITA	-10.1	-12.7	-13.6	-11.4	-8.4	-16.8	-17.2
Amortisation of intangible assets	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-10.3	-12.9	-13.8	-11.6	-8.6	-17.0	-17.4
<i>Margin</i>	<i>-552.0 %</i>	<i>-841.2 %</i>	<i>-1228.5 %</i>	<i>-1380.9 %</i>	<i>-1402.2 %</i>	<i>-2133.6 %</i>	<i>-1746.3 %</i>
EBIT adj.	-10.3	-12.9	-13.8	-11.6	-8.6	-17.0	-17.4
Interest income	0.0	0.0	0.2	0.0	0.0	0.0	0.0
Interest expenses	0.2	0.6	0.3	0.1	0.1	0.1	0.1
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	-10.4	-13.4	-14.0	-11.7	-8.7	-17.1	-17.5
<i>Margin</i>	<i>-560.6 %</i>	<i>-876.1 %</i>	<i>-1245.4 %</i>	<i>-1385.2 %</i>	<i>-1412.0 %</i>	<i>-2141.1 %</i>	<i>-1752.4 %</i>
Total taxes	-0.2	-0.7	-0.8	0.0	0.0	0.0	0.0
Net income from continuing operations	-10.2	-12.7	-13.2	-11.7	-8.7	-17.1	-17.5
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	-10.2	-12.7	-13.2	-11.7	-8.7	-17.1	-17.5
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-10.2	-12.7	-13.2	-11.7	-8.7	-17.1	-17.5
<i>Margin</i>	<i>-549.1 %</i>	<i>-827.9 %</i>	<i>-1173.8 %</i>	<i>-1387.9 %</i>	<i>-1412.0 %</i>	<i>-2141.1 %</i>	<i>-1752.4 %</i>
Number of shares, average	23.2	27.0	37.3	5.8	10.0	11.8	11.8
EPS	-0.44	-0.47	-0.35	-2.02	-0.86	-1.44	-1.48
EPS adj.	-0.42	-0.49	-0.35	-1.74	-0.86	-1.44	-1.48

*Adjustments made for: EBITDA before share-based payment expenses


Guidance: Revenues of EUR 0.4-1.0m, adjusted EBITDA of between EUR -7.0m to -9.0m

Financial Ratios

	2017	2018	2019	2020	2021e	2022e	2023e
Total Operating Costs / Sales	638.8 %	912.5 %	1304.6 %	1463.7 %	1484.0 %	2215.3 %	1831.5 %
Operating Leverage	0.3 x	-1.4 x	-0.3 x	0.6 x	1.0 x	3.3 x	0.1 x
EBITDA / Interest expenses	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Tax rate (EBT)	2.0 %	5.5 %	5.8 %	-0.2 %	0.0 %	0.0 %	0.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	40,522	34,841	26,163	21,590	16,574	21,546	26,932


Sales, EBITDA

in EUR m




Operating Performance

in %



Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Assets							
Goodwill and other intangible assets	0.7	0.5	0.3	0.1	0.0	-0.2	-0.4
thereof other intangible assets	0.2	0.1	0.3	0.1	0.0	-0.2	-0.4
thereof Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property, plant and equipment	0.7	0.7	1.5	1.2	0.8	0.4	0.0
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	1.4	1.2	1.9	1.3	0.7	0.2	-0.4
Inventories	0.3	0.4	0.3	0.1	0.1	0.1	0.1
Accounts receivable	0.9	0.2	0.1	0.3	0.1	0.1	0.1
Liquid assets	13.7	17.1	11.0	4.5	4.6	3.1	4.2
Other short-term assets	3.4	3.0	0.7	0.6	0.6	0.6	0.6
Current assets	18.4	20.7	12.1	5.5	5.3	3.9	5.0
Total Assets	19.8	21.8	14.0	6.8	6.1	4.0	4.6
Liabilities and shareholders' equity							
Subscribed capital	24.0	36.0	43.5	5.9	11.8	11.8	11.8
Capital reserve	59.5	68.8	69.3	87.4	88.0	88.0	88.0
Retained earnings	-73.1	-85.8	-102.8	-90.7	-99.4	-116.5	-133.9
Other equity components	0.2	-0.4	-0.3	1.3	2.1	2.1	2.2
Shareholders' equity	10.6	18.6	9.6	3.9	2.5	-14.5	-31.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	10.6	18.6	9.6	3.9	2.5	-14.5	-31.9
Provisions	1.1	1.0	1.3	1.4	1.4	1.4	1.4
thereof provisions for pensions and similar obligations	0.0	0.0	0.1	0.6	0.6	0.6	0.6
Financial liabilities (total)	6.5	0.0	0.0	0.0	1.1	16.1	34.1
Short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.0	1.4	1.4	0.6	0.1	0.1	0.1
Other liabilities	0.6	0.8	1.6	0.9	0.9	0.9	0.9
Liabilities	9.2	3.2	4.4	2.9	3.5	18.5	36.5
Total liabilities and shareholders' equity	19.8	21.8	14.0	6.8	6.1	4.0	4.6


Financial Ratios

	2017	2018	2019	2020	2021e	2022e	2023e
Efficiency of Capital Employment							
Operating Assets Turnover	1.9 x	-8.4 x	2.2 x	0.9 x	0.7 x	1.6 x	9.2 x
Capital Employed Turnover	0.5 x	1.0 x	-0.8 x	-16.9 x	-2.2 x	-0.9 x	-0.7 x
ROA	-737.4 %	-1080.2 %	-707.7 %	-880.0 %	-1165.4 %	-10802.9 %	4089.5 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
ROE	-81.9 %	-87.0 %	-93.5 %	-173.2 %	-270.8 %	284.3 %	75.2 %
Adj. ROE	-78.1 %	-90.9 %	-92.9 %	-149.4 %	-270.8 %	284.3 %	75.2 %
Balance sheet quality							
Net Debt	-7.2	-17.1	-11.0	-3.9	-2.8	13.7	30.5
Net Financial Debt	-7.2	-17.1	-11.0	-4.5	-3.4	13.1	29.9
Net Gearing	-67.6 %	-91.8 %	-113.9 %	-101.3 %	-111.3 %	-94.0 %	-95.8 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	0.5	0.7	0.2	0.7	0.2	-1.2	-2.7
Book value per share ex intangibles	0.4	0.7	0.2	0.6	0.2	-1.2	-2.7


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net income	-10.2	-12.7	-17.0	-11.7	-8.7	-17.1	-17.5
Depreciation of fixed assets	0.2	0.1	0.3	0.3	0.4	0.4	0.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Increase/decrease in long-term provisions	-0.7	-0.1	-0.4	0.3	0.0	0.0	0.0
Other non-cash income and expenses	0.4	0.9	3.2	0.8	0.0	0.0	0.0
Cash Flow before NWC change	-10.2	-11.6	-13.6	-10.0	-8.1	-16.5	-16.9
Increase / decrease in inventory	0.0	-0.1	0.0	0.2	0.0	0.0	0.0
Increase / decrease in accounts receivable	1.3	0.8	0.1	-0.2	0.2	0.0	0.0
Increase / decrease in accounts payable	0.9	-0.8	0.1	0.4	-0.5	0.0	0.0
Increase / decrease in other working capital positions	-1.5	1.3	-0.1	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	0.6	1.2	0.1	0.4	-0.4	0.0	0.0
Net cash provided by operating activities [1]	-9.6	-10.4	-13.5	-9.6	-8.4	-16.5	-16.9
Investments in intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Investments in property, plant and equipment	-0.2	-0.1	-0.1	-1.0	0.0	0.0	0.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.2	0.0	1.0	0.0	0.0
Net cash provided by investing activities [2]	-0.5	0.7	0.0	0.0	1.0	0.0	0.0
Change in financial liabilities	0.0	0.0	0.0	0.0	1.1	15.0	18.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	11.5	13.3	7.3	3.3	6.5	0.0	0.0
Other	0.0	0.0	-0.2	-0.3	-0.2	0.0	0.0
Net cash provided by financing activities [3]	11.5	13.3	7.1	3.0	7.5	15.0	18.0
Change in liquid funds [1]+[2]+[3]	1.4	3.6	-6.3	-6.6	0.0	-1.5	1.1
Effects of exchange-rate changes on cash	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	12.8	16.5	10.2	3.6	3.6	2.1	3.2

Financial Ratios


	2017	2018	2019	2020	2021e	2022e	2023e
Cash Flow							
FCF	-10.1	-9.6	-13.6	-9.6	-8.4	-16.5	-16.9
Free Cash Flow / Sales	-544.1 %	-629.1 %	-1211.4 %	-1138.0 %	-1374.7 %	-2067.7 %	-1693.7 %
Free Cash Flow Potential	-9.7	-11.9	-16.7	-11.1	-8.0	-16.4	-16.8
Free Cash Flow / Net Profit	99.1 %	76.0 %	103.2 %	82.0 %	97.4 %	96.6 %	96.6 %
Interest Received / Avg. Cash	0.1 %	0.1 %	1.1 %	0.3 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	5.4 %	16.8 %	n.a.	n.a.	10.5 %	0.7 %	0.2 %
Management of Funds							
Investment ratio	11.8 %	6.9 %	10.8 %	118.8 %	0.0 %	0.0 %	0.0 %
Maint. Capex / Sales	0.0 %	5.9 %	6.7 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	64.1 %	34.4 %	24.5 %	186.9 %	0.0 %	0.0 %	0.0 %
Avg. Working Capital / Sales	45.4 %	-19.7 %	-84.9 %	-76.2 %	-12.7 %	12.5 %	10.0 %
Trade Debtors / Trade Creditors	98.4 %	11.6 %	6.2 %	39.9 %	100.0 %	100.0 %	100.0 %
Inventory Turnover	0.8 x	1.2 x	0.9 x	1.2 x	1.1 x	1.5 x	1.5 x
Receivables collection period (days)	183	39	29	109	60	46	37
Payables payment period (days)	1,413	1,170	1,940	1,583	326	251	246
Cash conversion cycle (Days)	-794	-829	-1,486	-1,167	60	46	37

CAPEX and Cash Flow


in EUR m



Free Cash Flow Generation



Working Capital



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Epigenomics	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A3H2184.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	152	70
Hold	55	25
Sell	5	2
Rating suspended	4	2
Total	216	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	44	88
Hold	3	6
Sell	0	0
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY EPIGENOMICS AS OF 14.06.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Jonas Blum +49 40 309537-240
Telco, Media, Construction jblum@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Mustafa Hidir +49 40 309537-230
Automobiles, Car Suppliers mhidir@warburg-research.com

Ulrich Huwald +49 40 309537-255
Health Care, Pharma uhuwald@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Eggert Kuls +49 40 309537-256
Engineering ekuls@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate sstippig@warburg-research.com

Cansu Tatar +49 40 309537-248
Cap. Goods, Engineering ctatar@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Marc Niemann +49 40 3282-2660
Head of Equity Sales, Germany mniemann@mmwarburg.com

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lea Bogdanova +49 69 5050-7411
United Kingdom, Ireland lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Alexander Eschweiler +49 40 3282-2669
Germany, Luxembourg aeschweiler@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Maximilian Martin +49 69 5050-7413
Austria, Poland mmartin@mmwarburg.com

Christopher Seedorf +49 40 3282-2695
Switzerland cseedorf@mmwarburg.com

Sophie Hauer +49 69 5050-7417
Roadshow/Marketing shauer@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Elyaz Dust +49 40 3282-2702
Sales Trading edust@mmwarburg.com

Michael Ilgenstein +49 40 3282-2700
Sales Trading milgenstein@mmwarburg.com

Marcel Magiera +49 40 3282-2662
Sales Trading mmagiera@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Sales Trading jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

Thomson Reuters www.thomsonreuters.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com